Clinical Trial Update: A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

This document reports a long-term extension study of tocilizumab in rheumatoid arthritis, with the Phase 3 trial completed and results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2013-10-21